Herantis Pharma Plc. Company Profile, Contacts & Intelligence

Herantis Pharma Plc. Overview

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’s lead product, HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration. Primary objective of the ongoing Phase 1b clinical trial is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers and monitor symptoms associated with Parkinson’s disease. Topline data from Phase 1b trial is expected in September 2025. The Phase 1b trial is funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Parkinson’s Virtual Biotech. Herantis is listed on the Nasdaq First North Growth Market Finland.

Headquarters

Espoo, Uusimaa, Fi

Website

herantis.com

Industry

Biotechnology Research

Founded

2008

Stock Symbol

FIRST

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

Herantis Pharma Plc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Herantis Pharma Plc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Herantis Pharma Plc. Workforce Composition

Seniority breakdown across 8 visible profiles.

Compare Similar Companies to Herantis Pharma Plc.

Explore companies in related markets and compare their industry and employee estimates.